UBS AG set a GBX 1,550 ($20.38) price objective on GlaxoSmithKline plc (LON:GSK) in a research note issued to investors on Tuesday, www.boersen-zeitung.de reports. The brokerage currently has a neutral rating on the stock.
A number of other equities research analysts have also recently weighed in on GSK. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.98) price target on GlaxoSmithKline plc and gave the company a buy rating in a research note on Wednesday, July 26th. Barclays PLC restated an equal weight rating and issued a GBX 1,550 ($20.38) price target on shares of GlaxoSmithKline plc in a research note on Monday, July 3rd. Jefferies Group LLC restated a buy rating and issued a GBX 1,900 ($24.98) price target on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Deutsche Bank AG restated a hold rating and issued a GBX 1,720 ($22.61) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, July 25th. Finally, Liberum Capital restated a buy rating and issued a GBX 1,900 ($24.98) price target on shares of GlaxoSmithKline plc in a research note on Wednesday, August 30th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of GBX 1,689.48 ($22.21).
GlaxoSmithKline plc (LON GSK) opened at 1519.00 on Tuesday. The company’s market cap is GBX 74.25 billion. GlaxoSmithKline plc has a 12 month low of GBX 1,444.00 and a 12 month high of GBX 1,724.50. The company’s 50-day moving average is GBX 1,500.81 and its 200-day moving average is GBX 1,586.12.
WARNING: “UBS AG Reiterates GBX 1,550 Price Target for GlaxoSmithKline plc (GSK)” was first reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/10/13/ubs-ag-reiterates-gbx-1550-price-target-for-glaxosmithkline-plc-gsk.html.
The business also recently announced a dividend, which was paid on Thursday, October 12th. Stockholders of record on Thursday, August 10th were issued a dividend of GBX 19 ($0.25) per share. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend was Thursday, August 10th.
In related news, insider Manvinder Singh Banga bought 2,267 shares of GlaxoSmithKline plc stock in a transaction dated Wednesday, July 26th. The shares were bought at an average cost of GBX 1,599 ($21.02) per share, with a total value of £36,249.33 ($47,658.86). Over the last three months, insiders have bought 2,292 shares of company stock worth $3,662,755.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.